Moxatag is approved for the treatment of pharyngitis/tonsillitis secondary to Streptococcus pyogenes in patients 12 years and older. Moxatag is dosed once-daily at 775mg, versus the current most
QLT, a biopharmaceutical company, has reported encouraging results from a Phase Ia trial of QLT091001 in healthy adult volunteers. According to the company, the trial demonstrated that the
In accordance with XenoPort’s collaboration agreements with GlaxoSmithKline and Astellas Pharma the FDA’s acceptance of the new drug application (NDA) triggers milestone payments to XenoPort of $23 million
Dr Hamdy most recently served as therapeutic area head at Elan Pharmaceuticals responsible for gastroenterology and autoimmune clinical development. Dr Hamdy has also served as the general medicine
The agreement is part of both companies’ desire to complement their individual product lines so that their mutual customers will enjoy a consolidated cath lab solution. Combining the
BioMimetic Therapeutics, a developer and marketer of regenerative protein therapeutic-device combination products, has reported a net loss of $12.2m, or $0.65 per share, for the fourth quarter of
US-based Scolr Pharma has reported a net loss of $2.92m, or $0.07 per share, for the fourth quarter of 2008, compared to a net loss of $3.52m, or
Intra-Cellular Therapies, a biopharmaceutical company, has announced positive final results from the ITI-007 Phase II trial in patients with sleep maintenance insomnia. This Phase II trial was a
Rigel Pharmaceuticals has announced the enrollment of the first patient in a Phase II, multi-center clinical trial of R788 in patients with refractory or relapsed peripheral T-cell lymphoma.
NPS Pharmaceuticals, a biopharmaceutical company engaged in the development of specialty therapeutics to treat gastrointestinal and endocrine disorders, has reported a net loss of $8.48m, or $0.18 per
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.